Denis L, Robinson M, Mahler C, Smith P, Keuppens F, De Moura J L, Bono A, Newling D, Sylvester R, De Pauw M
A. Z. Middelheim, Antwerp, Belgium.
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):951-9. doi: 10.1016/0960-0760(90)90449-u.
A total of 327 patients with metastatic prostate cancer have been randomized to either orchidectomy or treatment with goserelin (Zoladez) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d. in a phase III study (EORTC 30853). A small but statistically significant difference in time to subjective and objective progression of disease was found in favour of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchidectomy. Thus no difference was found in overall survival between the two treatment groups. The clinical significance of these differences requires further follow up and analysis.
在一项III期研究（欧洲癌症研究与治疗组织30853）中，共有327例转移性前列腺癌患者被随机分为两组，一组接受睾丸切除术，另一组接受戈舍瑞林（Zoladez）3.6毫克长效制剂联合氟他胺（Eulexin）250毫克每日三次治疗。结果发现，联合治疗组在疾病主观和客观进展时间方面存在微小但具有统计学意义的差异。然而，最初分配接受睾丸切除术的组从客观进展到死亡的时间更长。因此，两个治疗组的总生存率没有差异。这些差异的临床意义需要进一步随访和分析。
